Differential Diagnosis of Adult Attention-Deficit/Hyperactivity Disorder: Treatment Options and Comorbidity Considerations (53 Minutes)

Faculty: David Goodman, MD, Roger McIntyre, MD, FRCPC, and Oscar Bukstein, MD, MPH

This CME Expert Review PsychCast™ is jointly sponsored by the Mount Sinai School of Medicine and MBL Communications.

Release Date: August 31, 2009
Termination Date: August 31, 2011

Estimated time to complete this activity: 1 hour

Medium: The content is delivered by PsychCast™ with a PDF or web-based Posttest

Acknowledgment of Commercial Support: Funding for this activity has been provided by an educational grant from Shire Pharmaceuticals Inc.

Activity Review Information: The activity content has been peer-reviewed and approved by James C.-Y. Chou, MD. Review Date: June 22, 2009.

Faculty Affiliation
David Goodman, MD, is director of the Adult Attention Deficit Disorder Center of Maryland and Suburban Psychiatric Associates in Lutherville, and assistant professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine in Maryland.

Roger McIntyre, MD, FRCPC, is associate professor of psychiatry and pharmacology at the University of Toronto, and head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada.

Oscar Bukstein, MD, MPH, is professor of psychiatry at the Western Psychiatric Institute and Clinic at the University of Pittsburgh School of Medicine in Pennsylvania.

CME Course Director James C.-Y. Chou, MD, is associate professor of psychiatry at Mount Sinai School of Medicine.

Faculty Disclosure Policy Statement
It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Faculty Disclosure
Dr. Goodman is a consultant to Eli Lilly, Forest, McNeil, New River, and Shire; is on the speaker’s bureaus of Forest, McNeil, Shire, and Wyeth; receives research support from Cephalon, Eli Lilly, Forest, McNeil, New River, and Shire; has received honoraria from Eli Lilly, Forest, McNeil, Shire, and Wyeth; and is an equity shareholder in Wyeth. Dr. Goodman discusses unapproved/investigational uses of bupropion for the treatment of attention-deficit/hyperactivity disorder.

Dr. McIntyre is on the advisory boards of AstraZeneca, Biovail, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Organon, Pfizer, Schering-Plough, Shire, and Solvay/Wyeth; is on the speaker’s bureaus of AstraZeneca, Biovail, Eli Lilly, Janssen-Ortho, Lundbeck, and Wyeth; receives grant/research support from Eli Lilly, Janssen-Ortho, the National Alliance for Research on Schizophrenia and Depression, Shire, and the Stanley Medical Research Institute; and receives honoraria from AstraZeneca, Bristol-Myers Squibb, and Solvay/Wyeth. Dr. McIntyre discusses unapproved/investigational uses of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.

Dr. Bukstein has received research support from Shire. Dr Bukstein discusses unapproved/investigational uses of bupropion and modafinil for the treatment of attention-deficit/hyperactivity disorder.

Dr. Chou has received honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, and Pfizer.

Learning Objectives

At the completion of this activity, participants should be better able to:
• Predict challenges to diagnosing and managing comorbidities in adults with ADHD
• Assess current evidence relating to treatment efficacy for adults with ADHD and comorbid depression, bipolar disorder, and substance use disorder
• Summarize the evidence related to ADHD and substance use disorder and how to minimize misuse and diversion when treating ADHD patients

Target Audience: This activity is designed to meet the educational needs of primary care physicians and psychiatrists.

Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The Mount Sinai School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclaimer: These are the opinions of the authors not of the sponsors or supporters. For more information, contact MBL Communications at cme@mblcommunications.com.

Minimum Hardware/Software Requirements

Macintosh: PowerPC processor, Mac OS 8.6, 9.0.4, 9.1, or Mac OS X, 64MB of RAM, 24MB of available hard-disk space, and Safari 1.x or 2.x.
Windows PC: Intel Pentium processor, Microsoft Windows 95 OSR 2.0, Windows 98 and 98 SE, Windows Millennium Edition, Windows NT 4.0 with Service Pack 5, Windows 2000, or Windows XP, 64MB of RAM, 24MB of available hard-disk space, and Internet Explorer 6.x and newer or Firefox 1.x and newer.

This CME Activity and Posttest information file is a PDF (Portable Document Format) document. To view this file, you will need Adobe Acrobat Reader, which is available free at www.adobe.com. Follow the instructions on that page to download and install the software.